Literature DB >> 33490663

Progranulin depletion inhibits proliferation via the transforming growth factor beta/SMAD family member 2 signaling axis in Kasumi-1 cells.

Kuniaki Yabe1,2, Yasuko Yamamoto1, Masao Takemura3, Takeshi Hara4, Hisashi Tsurumi4, Ginette Serrero5,6, Toshitaka Nabeshima3,7, Kuniaki Saito1,3,7,8.   

Abstract

Progranulin is an autocrine growth factor that promotes proliferation, migration, invasion, and chemoresistance of various cancer cells. These mechanisms mainly depend on the protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) pathway. Recent studies have shown that patients with hematopoietic cancer have elevated serum progranulin levels. Thus, the current study aimed to investigate the role of progranulin in hematopoietic cancer cells and how it modulates their proliferation. Both knockdown of progranulin and progranulin neutralizing antibody treatment inhibited proliferation in several human hematopoietic cancer cell lines. Moreover, progranulin depletion not only decreases the phosphorylation level of the Akt/mTOR pathway but also, surprisingly, increases the expression of transforming growth factor-beta (TGF-β) and phosphorylation of mothers against decapentaplegic homolog 2 (SMAD2) in Kasumi-1 cell. Furthermore, LY2109761, an inhibitor of TGF-β receptor type I/II kinase, and TGF-β neutralizing antibody blocked the inhibition of proliferation induced by progranulin depletion. These data provide new insights that progranulin alters cell proliferation via the TGF-β axis and progranulin could be a new therapeutic target for hematopoietic cancers.
© 2020 The Author(s).

Entities:  

Keywords:  Hematologic neoplasms; Mechanistic target of rapamycin complex 1; Progranulin; Transforming growth factor beta

Year:  2021        PMID: 33490663      PMCID: PMC7809376          DOI: 10.1016/j.heliyon.2020.e05849

Source DB:  PubMed          Journal:  Heliyon        ISSN: 2405-8440


  65 in total

1.  Progranulin overexpression predicts overall survival in patients with glioblastoma.

Authors:  Minqing Wang; Gang Li; Junyi Yin; Tao Lin; Jian Zhang
Journal:  Med Oncol       Date:  2011-12-13       Impact factor: 3.064

2.  PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.

Authors:  Wes E Kim; Ginette Serrero
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

3.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

4.  The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia.

Authors:  Yuan-xin Sun; Hai-li Kong; Chuan-fang Liu; Shuang Yu; Tian Tian; Dao-xin Ma; Chun-yan Ji
Journal:  Hum Immunol       Date:  2013-11-20       Impact factor: 2.850

Review 5.  Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth.

Authors:  Kazuyoshi Shiga; Masayasu Hara; Takaya Nagasaki; Takafumi Sato; Hiroki Takahashi; Hiromitsu Takeyama
Journal:  Cancers (Basel)       Date:  2015-12-11       Impact factor: 6.639

6.  Lack of Evidence for a Direct Interaction of Progranulin and Tumor Necrosis Factor Receptor-1 and Tumor Necrosis Factor Receptor-2 From Cellular Binding Studies.

Authors:  Isabell Lang; Simone Füllsack; Harald Wajant
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

7.  Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival.

Authors:  Thomas Greither; Kersten Fischer; Gerit Theil; Marios Marcou; Hans-Juergen Holzhausen; Katrin Weigelt; Ginette Serrero; David Hicks; Binbin Yue; Paolo Fornara; Bernd Wullich; Helge Taubert; Sven Wach; Verena Lieb
Journal:  Cancer Manag Res       Date:  2018-10-05       Impact factor: 3.989

8.  Growth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway.

Authors:  Tingting Feng; Lin Zheng; Feng Liu; Xiaoying Xu; Sheng Mao; Xiao Wang; Juan Liu; Yi Lu; Weiming Zhao; Xiuping Yu; Wei Tang
Journal:  Oncotarget       Date:  2016-09-06

9.  Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin.

Authors:  Simone Buraschi; Shi-Qiong Xu; Manuela Stefanello; Igor Moskalev; Alaide Morcavallo; Marco Genua; Ryuta Tanimoto; Ruth Birbe; Stephen C Peiper; Leonard G Gomella; Antonino Belfiore; Peter C Black; Renato V Iozzo; Andrea Morrione
Journal:  Oncotarget       Date:  2016-06-28

10.  HIF1/2-exerted control over glycolytic gene expression is not functionally relevant for glycolysis in human leukemic stem/progenitor cells.

Authors:  Alan Cunningham; Ayşegül Erdem; Nuria Vilaplana Lopera; Albertus T J Wierenga; Annet Z Brouwers-Vos; Maurien Pruis; André B Mulder; Ulrich L Günther; Joost H A Martens; Edo Vellenga; Jan Jacob Schuringa
Journal:  Cancer Metab       Date:  2019-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.